News and Trends 21 Jun 2017 British Biotech Tops up its Cancer Pipeline with New TCR Therapy Cell Medica just acquired Catapult Therapy TCR, set up by UK’s CGT Catapult, gaining the rights to its TCR therapy candidate to treat solid tumors. Cell Medica says it’s all set to leverage its Dominant T cell receptor (TCR) platform technology, which the company licensed from University College London (UCL) last year, to enhance existing T cell […] June 21, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jun 2017 Swedish Biotech publishes Long-Term Data on a Dendritic Cell Therapy for Cancer Immunicum has reported new data on long-term follow-up of patients treated with ilixadencel, a unique dendritic cell therapy against cancer. Immunicum is a Swedish biotech developing a cell-based therapy against cancer. The company has just published in the Journal for Immunotherapy for Cancer detailed results from a Phase I/II trial evaluating its lead candidate ilixadencel. The cell […] June 20, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jun 2017 Novartis Tops Ophthalmology Blockbuster Eylea in Phase III Trials Bayer’s and Regeneron’s blockbuster Eylea could be facing serious competition, as Novartis boasts with positive Phase III results for AMD. Novartis has been struggling on the age-related macular degeneration (AMD) market since its Roche-partnered VEGF-A inhibitor Lucentis was outperformed by Eylea from Bayer and Regeneron, which required a less-frequent dosing schedule and was placed at a lower […] June 20, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 19 Jun 2017 This Company Uses the Human Microbiome to Discover New Disease Mechanisms A whole new avenue to human health and disease could soon be accessible, thanks to the human tissue microbiome. Vaiomer has found a way to make it possible! Has anyone else ever been unsettled by the idea that the human body hosts about 10 times more microbes than human cells? Although this might seem an […] June 19, 2017 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jun 2017 Novartis Announces New Data for its Psoriasis Blockbuster Cosentyx Novartis has announced positive post-marketing results for its blockbuster Cosentyx, with which the pharma wants to compete with the best-selling drug. At the 2017 Annual European Congress of Rheumatology, currently being held in Madrid, Novartis has presented new data showing that Cosentyx (secukinumab) keeps improving symptoms of ankylosing spondylitis after three years of treatment and […] June 15, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jun 2017 UK-based VC Launches Massive $300M Fund to Fill Gap for Late-Stage Biotech The UK-based VC Medicxi has raised a massive $300M (€268M) fund backed by Novartis and Google’s Verily to invest in late-stage drug development. After the former life science branch of famous Index Ventures went solo in 2016 and became Medicxi, the VC was able to raise a huge sum of €210M in its first round to support early-stage, single-asset […] June 15, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jun 2017 MRC Technology, now LifeArc, Set to Invest £500M in UK’s Life Sciences LifeArc will draw funds from royalties of MSD’s successful checkpoint inhibitor Keytruda to invest in life sciences in both academic and business sectors. Born from the UK’s Medical Research Council, MRC Technology is a charity focused on supporting medical scientific research. Today, it becomes LifeArc and starts an ambitious new plan to invest up to […] June 15, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jun 2017 Where to Find the Perfect Mix of International and German Biotechs? Berlin! Germany’s capital city Berlin is the perfect meeting place for international and German biotech companies. See here why the city has become a hotspot for life sciences research institutions and businesses! “Berlin! Berlin! We’re going to Berlin!” It might be a phrase usually sung by football fans, but maybe it’s time to have it chanted by other […] June 15, 2017 - 6 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 14 Jun 2017 Understand your Biologics: De-Risking the Biotech Pipeline Characterizing biologics has become an essential step for successful drug development. We connected with SCIEX to learn how to tackle the biggest challenges. Biologics are taking over the market. Some of the top-selling drugs worldwide are antibodies and recombinant proteins, and new technologies such as Antibody-Drug Conjugates (ADCs) are on track to revolutionize the extremely […] June 14, 2017 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 14 Jun 2017 Results are in for Europe’s First Biobanking Study on HPV Cervical Cancer The RAIDs consortium made its closing event last week. After 4.5 years of studies, it has managed to change our appreciation of HPV cervical cancer towards building intelligent targeted therapy designs. Every year in Europe, 16,000 women die from cervical cancer and another 34,000 are newly diagnosed, which makes it the second most frequent form […] June 14, 2017 - 5 minutesmins - By Timothé Cynober Share WhatsApp Twitter Linkedin Email
News and Trends 14 Jun 2017 French Hepatitis Cure is on Track with Positive Phase I Results Enyo Pharma has announced that its lead candidate EYP001, indicated for the treatment of hepatitis B, successfully cleared a Phase Ia trial. Enyo Pharma is one of the hottest biotechs in Lyon that is developing new treatments against viruses, including hepatitis B or severe influenza infections. Its key asset, EYP001, is a farnesoid X receptor (FXR) agonist indicated […] June 14, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 13 Jun 2017 German Biotech Raises €25M to Fuel Diagnostics of Rare Diseases Centogene has raised €25M in a Series A round to support the global expansion of its genome analysis platform, which is specialized in rare diseases. The German biotech Centogene is pioneering the development of genetic diagnostic tests to address the challenges of personalized medicine in order to match therapies more effectively to patients. Founded in 2005, the […] June 13, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email